37 related articles for article (PubMed ID: 21446745)
1. Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
Zhao XZ; Maddali K; Metifiot M; Smith SJ; Vu BC; Marchand C; Hughes SH; Pommier Y; Burke TR
Bioorg Med Chem Lett; 2011 May; 21(10):2986-90. PubMed ID: 21493066
[TBL] [Abstract][Full Text] [Related]
2. Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors.
Zhang S; Zhang Y; Wang Z; Qing L; Fu S; Xu J; Li Y; Fang H; He H
Eur J Med Chem; 2023 Dec; 261():115836. PubMed ID: 37826932
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, Molecular Modeling Study and Biological Evaluation of New N'-Arylidene-pyrido [2,3-
Ebrahimzadeh E; Tabatabai SA; Vahabpour R; Hajimahdi Z; Zarghi A
Iran J Pharm Res; 2019; 18(Suppl1):237-248. PubMed ID: 32802103
[TBL] [Abstract][Full Text] [Related]
4. Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity.
Hajimahdi Z; Zarghi A
Iran J Pharm Res; 2016; 15(4):595-628. PubMed ID: 28243261
[TBL] [Abstract][Full Text] [Related]
5. The conformational feasibility for the formation of reaching dimer in ASV and HIV integrase: a molecular dynamics study.
Balasubramanian S; Rajagopalan M; Bojja RS; Skalka AM; Andrake MD; Ramaswamy A
J Biomol Struct Dyn; 2017 Dec; 35(16):3469-3485. PubMed ID: 27835934
[TBL] [Abstract][Full Text] [Related]
6. Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.
Watanabe M; Kasai M; Tomizawa H; Aoki M; Eiho K; Isobe Y; Asano S
ACS Med Chem Lett; 2014 Nov; 5(11):1235-9. PubMed ID: 25408837
[TBL] [Abstract][Full Text] [Related]
7. Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
Zhao XZ; Smith SJ; Métifiot M; Johnson BC; Marchand C; Pommier Y; Hughes SH; Burke TR
J Med Chem; 2014 Feb; 57(4):1573-82. PubMed ID: 24471816
[TBL] [Abstract][Full Text] [Related]
8. The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.
Wainberg MA
Scientifica (Cairo); 2012; 2012():238278. PubMed ID: 24278679
[TBL] [Abstract][Full Text] [Related]
9. HIV Drug Resistance and the Advent of Integrase Inhibitors.
Quashie PK; Mesplède T; Wainberg MA
Curr Infect Dis Rep; 2013 Feb; 15(1):85-100. PubMed ID: 23180144
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic strategies targeting HIV integrase.
Quashie PK; Sloan RD; Wainberg MA
BMC Med; 2012 Apr; 10():34. PubMed ID: 22498430
[TBL] [Abstract][Full Text] [Related]
11. Access to pyrrolo-pyridines by gold-catalyzed hydroarylation of pyrroles tethered to terminal alkynes.
Borsini E; Broggini G; Fasana A; Baldassarri C; Manzo AM; Perboni AD
Beilstein J Org Chem; 2011; 7():1468-74. PubMed ID: 22238519
[TBL] [Abstract][Full Text] [Related]
12. A potent and orally active HIV-1 integrase inhibitor.
Egbertson MS; Moritz HM; Melamed JY; Han W; Perlow DS; Kuo MS; Embrey M; Vacca JP; Zrada MM; Cortes AR; Wallace A; Leonard Y; Hazuda DJ; Miller MD; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Gabryelski LJ; Moyer G; Ellis JD; Jin L; Xu W; Braun MP; Kassahun K; Tsou NN; Young SD
Bioorg Med Chem Lett; 2007 Mar; 17(5):1392-8. PubMed ID: 17194584
[TBL] [Abstract][Full Text] [Related]
13. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.
Gardelli C; Nizi E; Muraglia E; Crescenzi B; Ferrara M; Orvieto F; Pace P; Pescatore G; Poma M; Ferreira Mdel R; Scarpelli R; Homnick CF; Ikemoto N; Alfieri A; Verdirame M; Bonelli F; Paz OG; Taliani M; Monteagudo E; Pesci S; Laufer R; Felock P; Stillmock KA; Hazuda D; Rowley M; Summa V
J Med Chem; 2007 Oct; 50(20):4953-75. PubMed ID: 17824681
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 integrase inhibitors: 2005-2006 update.
Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
[TBL] [Abstract][Full Text] [Related]
15. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors.
Johnson TW; Tanis SP; Butler SL; Dalvie D; Delisle DM; Dress KR; Flahive EJ; Hu Q; Kuehler JE; Kuki A; Liu W; McClellan GA; Peng Q; Plewe MB; Richardson PF; Smith GL; Solowiej J; Tran KT; Wang H; Yu X; Zhang J; Zhu H
J Med Chem; 2011 May; 54(9):3393-417. PubMed ID: 21446745
[TBL] [Abstract][Full Text] [Related]
17. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J
J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
